Celesa Therapeutics is set to present data from its global Phase 3 SURPASS-IPF trial of deupirfenidone at the European Respiratory Society Congress in Barcelona from September 5 to 9, 2026.
The SURPASS-IPF trial, registered under NCT07284602, enrolled approximately 1,100 adults with idiopathic pulmonary fibrosis (IPF) to compare deupirfenidone at 825 mg three times daily against pirfenidone at 801 mg three times daily. The primary endpoint is the change from baseline in absolute forced vital capacity at Week 52. Vincent Cottin of Louis Pradel Hospital will present the findings on September 6 at 8:00 AM CEST.
A separate Phase 1 study examining the co-administration of deupirfenidone and nintedanib found no clinically relevant drug-drug interactions, according to the company. Philip Molyneaux of Imperial College London will present these results on September 7 at 11:05 AM CEST.
Deupirfenidone is a deuterated form of pirfenidone and holds Orphan Drug Designation from the U.S. FDA and the European Commission. Earlier Phase 2b data, published in The American Journal of Respiratory and Critical Care Medicine, suggested the drug may stabilize lung function decline over at least 26 weeks. IPF is a progressive lung disease with a median survival of two to five years following diagnosis.
